Urine Phenylacetylglutamine Determination in Patients with Hyperphenylalaninemia

Andrade, Fernando; Cano, Ainara; Suarez, María Unceta; Arza, Arantza; Vinuesa, Ana; Ceberio, Leticia; López-Oslé, Nuria; Frutos, Gorka de; López-Oceja, Raquel; Aznal, Elena; González‐Lamuño, Domingo; Heras, Javier de las

doi:10.3390/jcm10163674

Cited by 5 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those with infections, malignant tumours, acute myocardial infarction and autoimmune diseases, those who had undergone renal replacement therapy, those who had used antibiotics within 4 weeks before enrolment and those who had undergone open‐heart surgery within 4 weeks before enrolment were excluded. Because PAGln levels can be elevated by phenylketonuria, 20 our patients were also excluded from this condition. HF was defined as cardiac systolic dysfunction with left ventricular ejection fraction (LVEF) ≤ 50%.…”

Section: Methodsmentioning

confidence: 99%

Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure

et al. 2022

View full text Add to dashboard Cite

AimsTo explore the associations between serum phenylacetylglutamine (PAGln) and chronic heart failure (HF). Methods and resultsTotally 956 subjects were enrolled consecutively from the Department of Cardiovascular Medicine, Ruijin Hospital. Baseline data were obtained from all participants, and 471 stable chronic HF subjects were followed up. Serum PAGln was analysed by liquid chromatography-tandem mass spectrometry. The association between PAGln and basic renal indicators was assessed by simple correlation analysis. Logistic regression analysis was conducted to measure the association between PAGln and HF risk. Event-free survival was determined by Kaplan-Meier curves, and differences in survival were assessed using log-rank tests. Cox proportional hazards analysis was used to assess the prognostic value of PAGln in HF. Serum PAGln levels were increased in patients with chronic HF (3.322 ± 8.220 μM vs. 1.249 ± 1.168 μM, P < 0.001) and were associated with HF after full adjustment [odds ratio (OR), 1.507; 95% confidence interval (CI): 1.213-1.873; P < 0.001]. PAGln levels were correlated with the levels of basic renal indicators. High PAGln levels indicated a high risk of renal dysfunction in HF (OR: 1.853; 95% CI: 1.344-2.556; P < 0.001), and elevated PAGln levels were associated with a high risk of cardiovascular death in patients with chronic HF (HR: 2.049; 95% CI: 1.042-4.029; P = 0.038). Conclusions Elevated PAGln levels are an independent risk factor for HF and are associated with a higher risk of cardiovascular death. High PAGln levels could indicate renal dysfunction in HF patients. PAGln can be a valuable indicator of HF.

show abstract

Section: Methodsmentioning

confidence: 99%

Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, the increased levels of phenylacetyl-L-glutamine 22 , 34 , 35 , 49 , 86 , a phenylalanine derivative, was identified in the blood and urine of PD patients in five studies. Phenylacetyl-L-glutamine was derived from phenylalanine through gut microbiota by decarboxylation and then conjugated with glutamine 87 , 88 . Therefore, the increased levels of phenylacetyl-L-glutamine are highly associated with the metabolism of phenylalanine and glutamine in PD, and reflect the high activity of gut microbiota in PD patients.…”

Section: Resultsmentioning

confidence: 99%

Identification of metabolites reproducibly associated with Parkinson’s Disease via meta-analysis and computational modelling

Luo,

Liu,

Balck

et al. 2024

npj Parkinsons Dis.

View full text Add to dashboard Cite

Many studies have reported metabolomic analysis of different bio-specimens from Parkinson’s disease (PD) patients. However, inconsistencies in reported metabolite concentration changes make it difficult to draw conclusions as to the role of metabolism in the occurrence or development of Parkinson’s disease. We reviewed the literature on metabolomic analysis of PD patients. From 74 studies that passed quality control metrics, 928 metabolites were identified with significant changes in PD patients, but only 190 were replicated with the same changes in more than one study. Of these metabolites, 60 exclusively increased, such as 3-methoxytyrosine and glycine, 54 exclusively decreased, such as pantothenic acid and caffeine, and 76 inconsistently changed in concentration in PD versus control subjects, such as ornithine and tyrosine. A genome-scale metabolic model of PD and corresponding metabolic map linking most of the replicated metabolites enabled a better understanding of the dysfunctional pathways of PD and the prediction of additional potential metabolic markers from pathways with consistent metabolite changes to target in future studies.

show abstract

“…The accession numbers of immune cells data were from GCST0001391 to GCST0002121, obtained from the GWAS Catalog provided by Valeria Orrù's group 42 . In this study, they pro led 731 immune cell traits and genotyped 22 million SNPs from 3,757 European individuals of unique family-based cohort, based on the high-density arrays or imputed through sequence-based reference panel.…”

Section: Data Sourcesmentioning

confidence: 99%

Causal associations of BAFF-R on IgD+ CD24- immune cell trait with hepatocellular carcinoma and the mediating role of phenylacetylglutamate levels: a Mendelian randomization study

Zhu,

Qiu,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

We conducted a bi-directional two-sample Mendelian randomization analysis to investigate the causal associations between immune cell traits and HCC and identify the mediating factor of metabolites. The exposure factors were immune cell traits, the mediators were metabolites, and the outcome variable was HCC. Inverse-variance weighted method (IVW) was the main method. Weighted median, MR-Egger regression, weighted mode, simple mode, and MR pleiotropy residual sum and outlier (MRPRESSO) methods were used as complementary methods. Subsequently, the potential mediating effect was investigated by conducting a two-step Mediation analysis. We found 7 traits with positive correlations and 19 traits with negative correlations between immune cell traits and HCC. There were no causal correlations between HCC and immune cell traits in the reverse MR analysis. In the mediation analysis, we found a positive causal association between B cell-activating factor receptors (BAFF-R) on IgD+ CD24- and HCC [IVW: odd ratio (OR), 0.845; 95% CI, 0.759-0.942; p = 0.002]. Phenylacetylglutamate (PAG) levels mediated 7.353% of the causal pathway from BAFF-R on IgD+ CD24- and HCC. In conclusion, BAFF-R on IgD+ CD24- lowers risk of HCC, with PAG levels playing a mediating role.

show abstract

Urine Phenylacetylglutamine Determination in Patients with Hyperphenylalaninemia

Cited by 5 publications

References 34 publications

Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure

Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure

Identification of metabolites reproducibly associated with Parkinson’s Disease via meta-analysis and computational modelling

Causal associations of BAFF-R on IgD+ CD24- immune cell trait with hepatocellular carcinoma and the mediating role of phenylacetylglutamate levels: a Mendelian randomization study

Contact Info

Product

Resources

About